-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The multi- disease burden of patients with psoriasis and the use of systemic immunosuppressive agents may increase the risk of poor prognosis of COVID-19 .
Immune to COVID-19
Clinicians report confirmed/suspected psoriasis patients with COVID-19 through an international registry, the Psoriasis Patient Registry of COVID-19 Infection Results, Treatment and Epidemiology.
infection
Among the patients reported by 374 clinicians from 25 countries, 71% were receiving biological treatments, 18% were receiving non-biological treatments, and 10% were not receiving any systemic treatment for psoriasis.
In summary, the results of the study indicate that in this international case series of patients with moderate to severe psoriasis, the use of biological agents is associated with a lower risk of hospitalization compared with the use of non-biological system therapies; however, considering the potential Selection bias and unassessed confounding factors require further investigation.
Original source:
Satveer K Mahil, et al.
ncbi.
Leave a message here
